Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.

Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. · 2013

Read Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. by Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3654568.txt.

Introduction

A diabetes drug works when kidneys are weak, Yale and nine colleagues report in Diabetes, Obesity and Metabolism in 2013. The drug, canagliflozin, blocks a kidney protein that pulls sugar back. The trial enrolled 269 people with type 2 diabetes and stage 3 kidney disease. Each got the drug at 100 or 300 milligrams, or a dummy pill, for 26 weeks.

Both doses cut the long-term blood sugar marker more than the dummy pill. The low dose cut it by a third of a point, the high dose by under half a point, while the dummy pill barely moved. More patients reached the target level on drug than on dummy pill: about 27 percent and 33 percent for the two doses, against 17 percent. Side effects ran the same across groups, though the high dose brought more water-passage infections and fluid-loss effects. Kidney measures shifted early, then drifted back.

Catalog record

CREATORYale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G.
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3654568

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease By J-F Yale, G Bakris, B Cariou, D Yue, E David-Neto, L Xi, K Figueroa, E Wajs, K Usiskin, G Meininger Published in: Diabetes, Obesity & Metabolism DOI: 10.1111/dom.12090 ABSTRACT Abstract Aims Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) ≥30 and <50 ml/min/1.73 m2]. Methods In this randomized, double-blind, placebo-controlled, phase 3 trial, subjects (N = 269) received canagliflozin 100 or 300 mg or placebo daily. The primary efficacy endpoint was change from baseline in HbA1c at week 26. Prespecified secondary endpoints were change in fasting plasma glucose (FPG) and proportion of subjects reaching HbA1c <7.0%. Safety was assessed based on adverse event (AE) reports; renal safety parameters (e.g. eGFR, blood urea nitrogen and albumin/creatinine ratio) were also evaluated. Results Both canagliflozin 100 and 300 mg reduced HbA1c from baseline compared with placebo at week 26 (–0.33, –0.44 and –0.03%; p < 0.05). Numerical reductions in FPG and higher proportions of subjects reaching HbA1c < 7.0% were observed with canagliflozin 100 and 300 mg versus placebo (27.3, 32.6 and 17.2%). Overall AE rates were similar for canagliflozin 100 and 300 mg and placebo (78.9, 74.2 and 74.4%). Slightly higher rates of urinary tract infections and AEs related to osmotic diuresis and reduced intravascular volume were observed with canagliflozin 300 mg compared with other groups. Transient changes in renal function parameters that trended towards baseline over 26 weeks were observed with canagliflozin. Conclusion Canagliflozin improved glycaemic control and was generally well tolerated in subjects with T2DM and Stage 3 CKD. Keywords: type 2 diabetes, sodium glucose co-transporter 2 (SGLT2) inhibitor, diabetic nephropathy INTRODUCTION Progression of chronic kidney disease (CKD), leading to end-stage renal failure, is a common complication in patients with type 2 diabetes mellitus (T2DM) 1. Antihyperglycaemic agent (AHA) treatment options are limited as a number of classes of agents may have decreased efficacy and be associated with increased risk of adverse effects in patients with CKD 2. For example, there are labelled restrictions on the use of thiazolidinediones, metformin, sulphonylureas, and, more recently, glucagon-like peptide-1 (GLP-1) agonists in this cohort 3,4. Moreover, AHAs commonly used in this population, such as sulphonylureas, have been associated with an increased risk of hypoglycaemia and weight gain 3–5. Thus, new treatment options are needed for this growing population of patients with co-existing T2DM and renal insufficiency 1. Canagliflozin is an inhibitor of the sodium glucose co-transporter 2 (SGLT2) in development for the treatment of patients with T2DM. Canagliflozin lowers the renal threshold for glucose (RTG) and increases urinary glucose excretion (UGE), resulting in decreased plasma glucose in patients with hyperglycaemia, as well as a mild osmotic diuresis and a net caloric loss (by loss of glucose) promoting weight loss 6–10. Because the rate of UGE is proportional to the glomerular filtration rate (GFR) (as well as to the blood glucose concentration) 7,8,11, the effect of canagliflozin to augment UGE would be anticipated to be diminished in subjects with CKD. Therefore, the efficacy of canagliflozin in improving glycaemic control and reducing body weight may be affected in this subject population. In addition to assessing the efficacy response to canagliflozin in this population, it is also important to assess the safety and tolerability profile of SGLT2 inhibition in subjects with CKD. This phase 3 study evaluated the efficacy and safety of canagliflozin compared with placebo in subjects with inadequately controlled T2DM and stage 3 CKD. This study included subjects with a lower, more restricted estimated glomerular filtration rate (eGFR) range of ≥30 and <50 ml/min/1.73 m2 based upon the modification of diet in renal disease (MDRD) equation 12, compared with the typical eGFR range for stage 3 CKD of ≥30 and <60 ml/min/1.73 m2 . MATERIALS AND METHODS Study Design and Subjects This 52-week, randomized, double-blind, placebo-controlled, phase 3 study was conducted at 89 centres in 19 countries and consisted of an AHA adjustment period (if required; consisting of a dose titration period of up to 4 weeks and an 8-week dose stable period); a 2-week, single-blind, placebo run-in period; a 26-week, double-blind, core treatment period; and a 26-week, double-blind, extension period (data to be reported in a separate publication). Eligible subjects were men and women aged ≥25 years with T2DM who had inadequate glycaemic control (HbA1c ≥7.0 and ≤10.5%) and stage 3 CKD (eGFR ≥30 and <50 ml/min/1.73 m2), and were either not on AHA therapy or were on a stable AHA regimen (monotherapy or combination therapy with any approved agent including metformin, sulphonylurea, dipeptidyl peptidase-4 (DPP-4) inhibitor, α-glucosidase inhibitor, GLP-1 analogue, pioglitazone or insulin) for ≥8 weeks (≥12 weeks with pioglitazone) prior to the week –2 visit. Subjects were required to have generally stable renal function, as determined by a ≤25% decrease in eGFR from the screening to the week –2 visits. Subjects on AHA regimens not consistent with local prescribing guidelines (e.g. metformin therapy) underwent an AHA adjustment period of up to 12 weeks before the placebo run-in period. Subjects were to remain on their stable AHA regimens through the completion of the 52-week treatment period (unless glycaemic rescue criteria were met, as discussed below). Subjects were excluded if they had repeated fasting plasma glucose (FPG) >15.0 mmol/l (270 mg/dl) during the pretreatment phase; a history of T1DM; renal disease that required immunosuppressive therapy, dialysis or transplant; nephrotic syndrome or inflammatory renal disease; New York Heart Association Class III-IV cardiovascular disease; myocardial infarction, unstable angina, revascularization procedure or cerebrovascular accident within 3 months prior to screening; or haemoglobin concentration <100 g/l (10 g/dl) at screening. The study protocol and amendments were approved by the institutional review boards at participating institutions and the study was conducted under the guidelines of Good Clinical Practices and the Declaration of Helsinki. All subjects provided written informed consent prior to participation. Randomization and Study Treatments Eligible subjects were randomly assigned to receive once-daily oral doses of canagliflozin 100 or 300 mg or placebo in a 1 : 1 : 1 ratio using an Interactive Voice Response System/Interactive Web Response System. Randomization was balanced by using permuted blocks of six subjects per block and stratified based on (i) the presence or absence of atherosclerotic cardiovascular disease (e.g. history of myocardial infarction, documented angina, transient ischemic attack or stroke or peripheral vascular disease) and (ii) whether a subject required an AHA adjustment period prior to randomization. During the double-blind, core treatment period, glycaemic rescue therapy (up-titration of current AHAs or step-wise addition of oral or non-oral AHAs) was initiated if FPG >15.0 mmol/l (270 mg/dl) after day 1 to week 6, >13.3 mmol/l (240 mg/dl) after week 6 to week 12, and >11.1 mmol/l (200 mg/dl) after week 12 to week 26. After randomization, HbA1c and FPG values were masked to the study centres unless these values met the prespecified glycaemic criteria for the initiation of rescue medication or after glycaemic rescue medication was started. Study Endpoints and Assessments The prespecified primary efficacy endpoint was the change from

Read the complete text